TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00008203
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01582165
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 20 mg once daily vs placebo for 6 months
Study: NCT01582165
Drug: Placebo.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily vs rosuvastatin for 6 months
Study: NCT00483899
Drug: GW870086X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will inhale 0.25 or 1.5 mg/inhalation GW870086X for four times
Study: NCT00483899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching GW870086X will be administered by subjects
Study: NCT00004099
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004099
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01550588
Drug: Standard medical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Medical management using anti-coagulant therapy
Study: NCT02468232
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: The target dose during the study was LCZ696 200 mg bid given orally. LCZ696 was supplied as 50 mg, 100 mg and 200 mg film-coated tablets.
Study: NCT02468232
Drug: Placebo to LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 Placebo 50 mg, 100 mg and 200 mg film-coated tablets
Study: NCT04065308
Drug: Drug Combinations
Normalized name: Other anti-dementia drug combinations in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab plus DCEP,combination therapy is administered total of three cycles,every 4weeks(28 days).~Daratumuamb 16mg/kg body weight in 500mL (the first dose,16mg/kg body weight in 1000mL) Weeks 1 to 8: weekly Weeks 9-24 : every 2 weeks if ASCT ineligible or PR but Plasmacytoma response \<CR: every 2 weeks for 12weeks and then every 4 weeks for 8weeks (Total of 8 times, additional administration of daratumumab) if ASCT eligible: From 6 to 12 weeks after ASCT, administration of daratumumab is initiated within 12 weeks of ASCT and twice a month for 12 weeks and then every a months for 8 weeks. (Total of 8 additional administration of daratumumab after ASCT)~1. dexamethasone :40mg/day D1-4, intravenous~2. cyclophosphamide: 400mg/m2 D1-4, intravenous~3. etoposide: 40mg/m2 D1-4, intravenous~4. cisplatin : 7mg/m2 D1-4, intravenous Pegteograstim: 6mg once, SC on day 5 or 6 of each 28-day cycle
Study: NCT02083315
Drug: TRV130 1.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV130 1.5 mg IV x 1 dose
Study: NCT02083315
Drug: TRV130 3 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV130 3 mg IV x 1 dose
Study: NCT02083315
Drug: TRV130 4.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV130 4.5 mg IV x 1 dose
Study: NCT02083315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 5% in water IV x 1 dose
Study: NCT00355628
Drug: KW-2246 (fentanyl citrate)
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: KW-2246
Study: NCT01421706
Drug: sibutramine-Clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: sibutramine-Clarithromycin
Study: NCT00758849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo tablet administered tid for 12 days in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
Study: NCT00995410
Drug: PA32540
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole to be taken by mouth once daily
Study: NCT00146523
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00713323
Drug: Sativex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
Study: NCT03478280
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
Study: NCT00818883
Drug: Azilsartan medoxomil and chlorthalidone
Normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of chlorthalidone will be increased for the remaining 4 weeks of treatment.
Study: NCT02127853
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the same regimen of placebo drug is prescribed to the patient for 1 week after the first eye surgery
Study: NCT04149626
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sedation using remifentanil (initial bolus dose followed by continuous infusion)
Study: NCT00437177
Drug: [(123)I] iodobenzamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[(123)I\] iodobenzamide 185 MBq I.V., at discharge.
Study: NCT01458236
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group
Study: NCT00818883
Drug: Azilsartan medoxomil and hydrochlorothiazide
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of hydrochlorothiazide will be increased for the remaining 4 weeks of treatment.
Study: NCT02840565
Drug: BIA 5-453
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presented as blue hard gelatine capsules (size 2) of 1 mg, 10 mg and 50 mg for oral administration
Study: NCT02840565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient.
Study: NCT00939653
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 440 mg/m2/day IV as a 30-60 minute infusion (given at hours 4 to 5) on days 1 through 5.
Study: NCT04480398
Drug: Guduchi Ghan Vati
Normalized name: vatinoxan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guduchi Ghan Vati is an Ayuvedic classical preparation which is prepared from aqueous of extract of Tinospora cordifolia.
Study: NCT01050855
Drug: RIC: Distal Campath
Approvals — FDA: no, EMA: no, PMDA: no
Description: Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
Study: NCT01050855
Drug: RIC:Intermediate Campath
Approvals — FDA: no, EMA: no, PMDA: no
Description: Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
Study: NCT01582204
Drug: 124IcG250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pts will undergo baseline disease assessment with CT scans (chest, abd \& pelvis), 124I-cG250-PET/CT \& Tc99mMDP bone scan. W/I 7 days of their lst 124I-cG250 PET/CT, pts will start tx with sunitinib or pazopanib, dosed in successive 6-week cycles. At selected time points during the sunitinib or pazopanib cycle 1, repeat imaging with CT scan \& 124I-cG250 PET/CT will be performed. After cycle 2, pts will be followed per standard of care, i.e., pts will have a standard CT scan of the chest, abd, \& pelvis with contrast after cycles 2, 3, 4 \& 6 (or at the time of disease progression if prior to cycle 6) for determination of best response using RECIST 1.1. Each pt will have 2 124I-cG250-PET/CT scans: baseline \& week 4 (during sunitinib or pazopanib tx). All experimental imaging will take place during tx cycle 1. There will be a dosimetry sub-study for pts willing to undergo 3 additional PET/CT scans, whole body counts, \& serial blood sampling, following the lst inj of 124I-cG250.
Study: NCT02010762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo oral drops
Study: NCT00569062
Drug: GW856553X
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW856553X 7.5mg BID for 6 weeks
Study: NCT01485965
Drug: SEN0014196
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg, immediate release tablets, once daily administration
Study: NCT00944671
Drug: famotidine (+) calcium carbonate (+) magnesium hydroxide tablet
Normalized name: calcium carbonate / famotidine / magnesium hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of famotidine/antacid tablet with 120 mL of water in one of three treatment periods
Study: NCT00944671
Drug: Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without water
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of famotidine/antacid combination EZ Chew tablet without water in one of three treatment periods
Study: NCT01624376
Drug: DLX105
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg DLX105/injection injected into the fistula over a treatment period of 4 weeks.
Study: NCT01624376
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections are administered over the treatment period of 4 weeks.
Study: NCT00944671
Drug: Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with water
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of famotidine/antacid combination EZ Chew tablet with 120 mL of water in one of three treatment periods
Study: NCT00775034
Drug: Tisseel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesh repair for open incisional hernia repair with fibrin sealant
Study: NCT00674297
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvastatin 40 mg daily for 3 months
Study: NCT04919421
Drug: Dental injection and topical gel application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia gel will be applied followed by dental injection with 1.8 ml Xylocaine 20mg/ml (DENSPLY Pharmaceutical); adrenaline: 1 : 100.000, delivered in cartridges using a 27 -gauge short needle (0.4 x 25 mm,C-K jet) and sterile non-aspirating syringe.
Study: NCT02678975
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram 400 mg daily
Study: NCT02678975
Drug: Alkylating Agents
Normalized name: ALKYLATING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkylating antineoplastic agent
Study: NCT00621530
Drug: ketorolac tromethamine opthalmic solution
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketorolac 2 mg will be added to the patient's routine spinal anesthetic for surgery
Study: NCT04286750
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered as hard capsules for oral use.
Study: NCT00621530
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo will be added to the patient's routine spinal anesthetic for surgery
Study: NCT01255020
Drug: α-Keto Acid with restricted protein diet
Normalized name: Keto-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-Keto Acid: The daily dose of compound α-Keto Acid is 100mg/kg/d. The total daily dose will be divided into three times a day.~Restricted Protein Diet: Diet contain protein 1.0g/kg/d
Study: NCT01255020
Drug: Placebo plus restricted protein diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo: The daily dose of placebo is 100mg/kg/d. The total daily dose will be divided into three times a day.~Diet contain protein 1.0 g/kg/d.
Study: NCT03414632
Drug: 99mTc-PYP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioisotope used in the SPECT/CT imaging
Study: NCT00227448
Drug: intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03949530
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00699504
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo IV and oral
Study: NCT05116228
Drug: 500mg RTX Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 1x500mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
Study: NCT05116228
Drug: 1000mg RTX Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 1x1000mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
Study: NCT00977288
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, once daily for 8 weeks
Study: NCT04462263
Drug: HTL0014242
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid suspension capsule
Study: NCT00795574
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period.
Study: NCT03825809
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-Operative Non Opioid Pain Protocol
Study: NCT03825809
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-Operative Non Opioid Pain Protocol
Study: NCT03825809
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-Operative Non Opioid Pain Protocol
Study: NCT00449150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01146483
Drug: Rosuvastatin, Pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin, 10 mg tablets, single dose on the morning~Concomitant drug: Pantoprazole; 40 mg tablets, 2 single doses administered 1 hour before rosuvastatin and 23 hours after rosuvastatin administration. A placebo is given on the other period as a crossover design study.
Study: NCT04139135
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant treatment phase：placebos（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：SOX
Study: NCT02214472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00471965
Drug: Oxaliplatin + 5-Fluorouracil/Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks
Study: NCT00471965
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1: Doxorubicin 50mg/m² iv infusion. Repeated every 3 weeks.
Study: NCT04132661
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: one single dose
Study: NCT01030536
Drug: CAT-8015 20 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
Study: NCT01030536
Drug: CAT-8015 30 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
Study: NCT01030536
Drug: CAT-8015 40 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
Study: NCT01030536
Drug: CAT-8015 50 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
Study: NCT01030536
Drug: CAT-8015 60 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
Study: NCT00304746
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AndroGel 2.5g and 5g sachets at doses ranging from 10g/day for duration of trial.
Study: NCT00304746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02261896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluate usefullness of antibiotic prophylaxis
Study: NCT00600925
Drug: gentamicin-collagen sponge dipped in saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 gentamicin-collagen sponges inserted before closure of the laparotomy
Study: NCT03582332
Drug: Indomethacin SR, 75 Mg Oral Capsule, Extended Release
Normalized name: Indomethacin SR, 75 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin SR, 75 Mg Oral Capsule, Extended Release orally twice daily
Study: NCT03582332
Drug: Indomethacin 25 Mg Oral Capsule
Normalized name: Indomethacin 25 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 Mg Oral Capsule, 2 capsule orally twice daily
Study: NCT03582332
Drug: Etoricoxib 90 mg
Normalized name: etoricoxib 90 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 90 mg once daily orally
Study: NCT03582332
Drug: Etoricoxib 60 mg
Normalized name: etoricoxib 60 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 mg once daily orally
Study: NCT02107898
Drug: Placebo (for alirocumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
Study: NCT01074554
Drug: Antibiotic Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg QD Azithromycin 500mg on day 1, then 250 mg po QD Rifampin 5-10 mg/kg for a maximum of 300mg po QD All four drugs are given concomitanly
Study: NCT02107898
Drug: Lipid-Modifying Therapy (LMT)
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.
Study: NCT00204737
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01873144
Drug: Epinephrine 1/1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulization of 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 every 4h for three times and afterwards at physician in charge criteria
Study: NCT01873144
Drug: HSS 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulization 2 mL of HSS (3%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
Study: NCT01431989
Drug: Amoxil® 500mg/5mL powder for oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation
Study: NCT04423276
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
Study: NCT03847246
Drug: Baraclude® tablets,1.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral,once,under fasting condition
Study: NCT00531271
Drug: ABI-008 (nab-docetaxel)
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI-008; 60-200 mg/m²; Intravenous infusion every 3 weeks.
Study: NCT02147470
Drug: Definity ultrasound contrast agent
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will undergo CEUS of the kidney at baseline to measure renal blood flow. This procedure will be repeated after volume expansion and if indicated, once again after treatment with albumin, midodrine and octreotide.
Study: NCT00623779
Drug: AZD0837
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER formulation
Study: NCT03345914
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection;~Route of administration: Subcutaneous (SC)
Study: NCT01199861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules for oral administration.
Study: NCT01456611
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac Sodium Gel 1%
Study: NCT01456611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Topical Gel
Study: NCT04396301
Drug: Fydrane®: (Manufacturer DELPHARM TOURS, FRANCE).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fydrane®. The active substances in Fydrane are: tropicamide 0.04 mg (anticholinergic), phenylephrine hydrochloride 0.62 mg (alpha sympathomimetic) and Lidocaine hydrochloride 2 mg (amide type local anaesthetics) for each 0.2 ml dose, equivalent to 0.2 mg of tropicamide, 3.1 mg of phenylephrine hydrochloride and 10 mg of lidocaine hydrochloride for 1 ml.
Study: NCT00965653
Drug: folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: \>/= 5 mg po weekly
Study: NCT00965653
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7.5 - 25 mg weekly (oral or parenteral)
Study: NCT00718679
Drug: IVN201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralymphativ injection of the study drug
Study: NCT00718679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02459301
Drug: IPH2201
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01951274
Drug: VPD-737
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK1 Receptor Antagonist
Study: NCT01951274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02569658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04020380
Drug: Azithromycin 250Mg Capsule
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg OD
Study: NCT02222740
Drug: 10 mg of Hydrocodone Bitartrate Extended Release (HC-ER)
Normalized name: hydrocodone
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Schedule II Class